ID22977A - Konjugasi polietilen glikol-interferon alfa untuk terapi suatu infeksi - Google Patents

Konjugasi polietilen glikol-interferon alfa untuk terapi suatu infeksi

Info

Publication number
ID22977A
ID22977A IDW991297A ID991297A ID22977A ID 22977 A ID22977 A ID 22977A ID W991297 A IDW991297 A ID W991297A ID 991297 A ID991297 A ID 991297A ID 22977 A ID22977 A ID 22977A
Authority
ID
Indonesia
Prior art keywords
conjugation
polyethylene glycol
interferon alfa
infection
therapy
Prior art date
Application number
IDW991297A
Other languages
English (en)
Inventor
Paul Glue
David I Cutler
Melton B Affrime
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ID22977A publication Critical patent/ID22977A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IDW991297A 1997-04-29 1998-04-20 Konjugasi polietilen glikol-interferon alfa untuk terapi suatu infeksi ID22977A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/839,101 US5908621A (en) 1995-11-02 1997-04-29 Polyethylene glycol modified interferon therapy

Publications (1)

Publication Number Publication Date
ID22977A true ID22977A (id) 1999-12-23

Family

ID=25278858

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991297A ID22977A (id) 1997-04-29 1998-04-20 Konjugasi polietilen glikol-interferon alfa untuk terapi suatu infeksi

Country Status (26)

Country Link
US (3) US5908621A (id)
EP (1) EP0975369B1 (id)
JP (1) JP2001524110A (id)
KR (1) KR20010020355A (id)
CN (1) CN1261806A (id)
AR (1) AR012614A1 (id)
AT (1) ATE255421T1 (id)
AU (1) AU7249098A (id)
BR (1) BR9809425A (id)
CA (1) CA2288038C (id)
CO (1) CO4940414A1 (id)
DE (1) DE69820247T2 (id)
DK (1) DK0975369T3 (id)
ES (1) ES2207830T3 (id)
HU (1) HUP0003131A2 (id)
ID (1) ID22977A (id)
IL (1) IL132582A0 (id)
MY (1) MY133891A (id)
NO (1) NO995263L (id)
NZ (1) NZ500763A (id)
PE (1) PE72799A1 (id)
PL (1) PL336576A1 (id)
PT (1) PT975369E (id)
SK (1) SK149199A3 (id)
WO (1) WO1998048840A1 (id)
ZA (1) ZA983543B (id)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2302834A1 (en) * 1997-09-18 1999-03-25 F. Hoffmann-La Roche Ag Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
SK285284B6 (sk) * 1998-03-26 2006-10-05 Schering Corporation Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
KR100694345B1 (ko) * 1998-05-15 2007-03-12 쉐링 코포레이션 리바비린 및 인터페론 알파를 포함하는, 만성 ｃ형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
TR200003635T2 (tr) * 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
EP1113794A2 (en) * 1998-09-14 2001-07-11 Vertex Pharmaceuticals Incorporated Methods of treating viral disease
EE05111B1 (et) 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
EP1140143A2 (en) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2299893A1 (en) * 1999-03-02 2000-09-02 Carlos O. Stalgis Hiv therapy
CO5170411A1 (es) * 1999-04-08 2002-06-27 Schering Corp Terapia para la leucemia mielocitica cronica
CA2303992A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Melanoma therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
ATE419002T1 (de) * 1999-04-08 2009-01-15 Schering Corp Behandlung von nierenzellen-karzinom
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
EP1175224B1 (en) * 1999-05-04 2005-02-23 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
PE20010490A1 (es) * 1999-08-13 2001-04-27 Hoffmann La Roche Micofenolato mofetil en asociacion con peg-ifn-alfa
WO2001022970A1 (en) * 1999-09-29 2001-04-05 The Cleveland Clinic Foundation Therapy with 2-5a and interferon
JP2001288109A (ja) * 2000-04-06 2001-10-16 Schering Plough Corp 黒色腫治療
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) * 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
WO2002011754A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin and pegylated interferon
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002026265A2 (en) * 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
BR0115392A (pt) * 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
JP2005500247A (ja) * 2000-12-07 2005-01-06 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム ヒトｍｄａ−７に関わる処置方法
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
BR0213103A (pt) * 2001-10-05 2004-09-21 Intermune Inc Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
BR0213861A (pt) * 2001-11-02 2004-12-21 Sandoz Ag Processo para a preparação de composições de ribavirina de carga elevada, de dissolução rápida
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
DK1476181T3 (en) * 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
JP2005533000A (ja) * 2002-03-05 2005-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｍｄａ−７に関与する免疫誘導を増強する方法
WO2003101199A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
AP2005003213A0 (en) * 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003256125A1 (en) 2002-08-31 2004-03-19 Cj Corp. Glycosylated human interferon alpha isoform
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
AU2003295395A1 (en) * 2002-11-04 2004-06-07 4Life Research, Lc Compositions, systems, and methods for focusing a cell-mediated immune response
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
CA2506415A1 (en) 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
WO2004048971A1 (en) 2002-11-25 2004-06-10 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
BR0215954A (pt) * 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
MXPA05006230A (es) * 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
BRPI0408063A (pt) * 2003-03-03 2006-02-14 Univ Texas métodos e composições envolvendo mda-7
WO2004093901A1 (en) * 2003-03-28 2004-11-04 Intermune, Inc. Compositions and methods for treating poxvirus infection
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
SG169362A1 (en) * 2004-05-14 2011-03-30 Sciclone Pharmaceuticals Inc Treatment or prevention of respiratory viral infections with immunomodulator compounds
JP2008506648A (ja) * 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト Ｃ型肝炎（ｈｃｖ）処置のためのシクロスポリンとペグ化インターフェロンの組合せ剤の使用
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
BRPI0515279A (pt) * 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US7897565B2 (en) * 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
RU2007128098A (ru) * 2004-12-23 2009-01-27 Новартис АГ (CH) Соединения для лечения инфекций, вызываемых вирусами семейства flaviviridae
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101257925A (zh) * 2005-06-20 2008-09-03 派普根公司 人干扰素α类似物和干扰素τ的低毒长循环的嵌合体
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
BRPI0617274A2 (pt) 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
EP1985303B1 (en) 2006-01-12 2012-11-21 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Oral composition containing Interferon-alpha
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8114150B2 (en) * 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
KR20090040906A (ko) * 2006-08-02 2009-04-27 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 리포솜 치료
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
CA2666814A1 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
SG175621A1 (en) * 2006-10-12 2011-11-28 Novartis Ag Use of modified cyclosporins
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
DK2279007T3 (en) 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2729322C (en) 2008-06-24 2020-05-26 Technische Universitaet Muenchen Muteins of hngal and related proteins with affinity for a given target
BRPI0918653A2 (pt) * 2008-09-17 2015-12-01 Boehringer Ingelheim Int combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
JP5888980B2 (ja) 2008-12-17 2016-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． モノ−およびジ−ｐｅｇｉｌ１０の製造および用途
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
EP2410989A2 (en) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
BR112012002709A2 (pt) 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP3660510A3 (en) 2009-12-07 2020-07-08 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
US8986951B2 (en) 2010-06-08 2015-03-24 Pieris Ag Tear lipocalin in muteins binding IL-4 R alpha
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Pharmaceuticals Gmbh Binding proteins for hepcidin
KR20140035305A (ko) 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
EP2640740B1 (en) 2010-11-15 2017-03-15 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CN105381450A (zh) 2010-11-30 2016-03-09 诺华有限公司 丙型肝炎病毒感染的新疗法
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN105749246A (zh) 2011-03-31 2016-07-13 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
RS53911B1 (sr) 2011-04-01 2015-08-31 Novartis Ag Tretman u infekciji virusom hepatitis b zasebno ili u kombinaciji sa hepatitis delta virusom i bolesti jetre koje ih prate
KR20140011379A (ko) 2011-04-13 2014-01-28 노파르티스 아게 알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료
JP2014528947A (ja) 2011-09-27 2014-10-30 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の治療のためのアリスポリビル
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2863410T3 (es) 2011-12-13 2021-10-11 Pieris Pharmaceuticals Gmbh Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores.
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP2968490A1 (en) 2013-03-14 2016-01-20 Daiichi Sankyo Co., Ltd. Novel binding proteins for pcsk9
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
SG10201912019WA (en) 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
US10799563B2 (en) 2014-11-18 2020-10-13 Ascendis Pharma Endocrinology Division Polymeric hGH prodrugs
PL3220892T3 (pl) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Postacie dawkowane długo działającego hormonu wzrostu
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
BR112017017530A2 (pt) 2015-02-18 2018-04-17 Sanofi proteínas específicas para pioverdina e pioquelina
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
RU2736312C2 (ru) 2015-05-04 2020-11-13 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Белки, специфичные в отношении cd137
AU2016262845B2 (en) 2015-05-18 2020-07-23 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
KR20180029238A (ko) 2015-07-15 2018-03-20 피어이스 파마슈티컬즈 게엠베하 Lag-3에 특이적인 신규 단백질
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
EA035586B1 (ru) 2015-11-30 2020-07-10 Пиерис Острелиа Пти Лтд. Новые антиангиогенные слитые белки
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7093311B2 (ja) * 2016-06-20 2022-06-29 エランコ・ユーエス・インコーポレイテッド ペグ化ブタインターフェロンおよびその使用方法
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2018134274A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
HRP20230590T2 (hr) 2018-07-31 2024-02-16 Pieris Pharmaceuticals Gmbh Novi fuzijski protein specifičan za cd137 i pd-l1
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
SG11202108735QA (en) 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
JP2023527908A (ja) 2020-06-05 2023-06-30 ピエリス ファーマシューティカルズ ゲーエムベーハー ４－１ｂｂをターゲティングする多量体免疫調節物質
EP4320141A1 (en) 2021-04-08 2024-02-14 Pieris Pharmaceuticals GmbH Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
MX9307733A (es) 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
CA2236591C (en) * 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Also Published As

Publication number Publication date
NZ500763A (en) 2002-03-01
NO995263L (no) 1999-12-27
JP2001524110A (ja) 2001-11-27
AU7249098A (en) 1998-11-24
IL132582A0 (en) 2001-03-19
US6177074B1 (en) 2001-01-23
ZA983543B (en) 1998-11-10
PT975369E (pt) 2004-04-30
US6524570B1 (en) 2003-02-25
CA2288038C (en) 2003-07-29
PE72799A1 (es) 1999-08-06
BR9809425A (pt) 2000-07-25
CO4940414A1 (es) 2000-07-24
NO995263D0 (no) 1999-10-28
DE69820247T2 (de) 2004-09-09
WO1998048840A1 (en) 1998-11-05
ATE255421T1 (de) 2003-12-15
EP0975369A1 (en) 2000-02-02
DK0975369T3 (da) 2004-04-05
KR20010020355A (ko) 2001-03-15
PL336576A1 (en) 2000-07-03
DE69820247D1 (de) 2004-01-15
US5908621A (en) 1999-06-01
AR012614A1 (es) 2000-11-08
CA2288038A1 (en) 1998-11-05
CN1261806A (zh) 2000-08-02
HUP0003131A2 (hu) 2001-11-28
ES2207830T3 (es) 2004-06-01
EP0975369B1 (en) 2003-12-03
MY133891A (en) 2007-11-30
SK149199A3 (en) 2000-11-07

Similar Documents

Publication Publication Date Title
ID22977A (id) Konjugasi polietilen glikol-interferon alfa untuk terapi suatu infeksi
IS5425A (is) Læknislyf
BR9707791A (pt) Corpo ótico
BR9707766A (pt) Corpo ótico
DE59805003D1 (de) Steriler konnektor
DE69835847D1 (de) Wegwerfhöschen
ID24118A (id) Terapi gabungan
DE69723175D1 (de) Katheter mit internen Versteifungsgegenständen
ID24275A (id) Terapi kombinasi
DE69713474D1 (de) Wegwerfhöschen
FR2763699B1 (fr) Detecteur-optoelectronique
ID27841A (id) Turunan-turunan biaril terapeutik
ATE253951T1 (de) Katheterverpackung
PT925083E (pt) Seringas
DE69825982D1 (de) Spritze
NO992806L (no) Terapeutiske midler
DE59804367D1 (de) Sterilisierbehälter
DE59802830D1 (de) Orthesengelenk
DE69812588D1 (de) Medizinischer injektor
DE59812561D1 (de) Injektions- oder Verpresskörper
NO983090D0 (no) Terapeutiske forbindelser
DE59711146D1 (de) Cpkd-karosserie
PT876164E (pt) Corpo absorvente melhorado
DE59701536D1 (de) Fibrillationsarmer formkörper
FI965196L (fi) HIV-infektion yhdistelmähoito